This site is intended for health professionals only
Monday 27 May 2019
Share |

Stroke risk with ranibizumab

Genentech advises US doctors over clinical trial results

Genentech Inc has sent a letter to doctors in the USA, advising them of the results of an interim analysis of a trial of ranibizumab (Lucentis). According to these preliminary results, 1.2% of patients given a 0.5mg dose of the drug suffered a stroke, compared with 0.3% of those given a 0.3mg dose.

According to a company spokesperson, these findings are consistent with data from previous trials. In addition, it appears that patients who had a previous stroke are at greater risk of another stroke.

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher